 Immunocore announces strategic priorities including pipeline expansion for 2023 2024 KIMMTRAK tebentafusp-tebn approved in over 30 countries with continued global expansion in 2023-2024; preliminary unaudited net sales of 50 million in Q4 and 140 million for full year 2022 Priority for IMC-F106C PRAME HLA-A02 is enrollment in monotherapy and combination arms of Phase 12 clinical... The post Immunocore announces strategic priorities including pipeline expansion for 2023 -2024 appeared fir... 